|
1
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Medici D, Hay ED and Olsen BR: Snail and
Slug promote epithelial-mesenchymal transition through
beta-catenin-T-cell factor-4-dependent expression of transforming
growth factor-beta3. Mol Biol Cell. 19:4875–4887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moustakas A: Smad signalling network. J
Cell Sci. 115:3355–3356. 2002.PubMed/NCBI
|
|
7
|
Dowling RJ, Niraula S, Stambolic V and
Goodwin PJ: Metformin in cancer: Translational challenges. J Mol
Endocrinol. 48:R31–R43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kourelis TV and Siegel RD: Metformin and
cancer: New applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cufi S, Vazquez-Martin A,
Oliveras-Ferraros C, Martin-Castillo B, Joven J and Menendez JA:
Metformin against TGFβ-induced epithelial-to-mesenchymal transition
(EMT): From cancer stem cells to aging-associated fibrosis. Cell
Cycle. 9:4461–4468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tan BK, Adya R, Chen J, Lehnert H, Cassia
Sant LJ and Randeva HS: Metformin treatment exerts antiinvasive and
antimetastatic effects in human endometrial carcinoma cells. J Clin
Endocrinol Metab. 96:808–816. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Naujokat C, Fuchs D and Opelz G:
Salinomycin in cancer: A new mission for an old agent. Mol Med Rep.
3:555–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bardsley MR, Horváth VJ, Asuzu DT, Lorincz
A, Redelman D, Hayashi Y, Popko LN, Young DL, Lomberk GA, Urrutia
RA, et al: Kitlow stem cells cause resistance to
Kit/platelet-derived growth factor alpha inhibitors in murine
gastrointestinal stromal tumors. Gastroenterology. 139:942–952.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fuchs D, Daniel V, Sadeghi M, Opelz G and
Naujokat C: Salinomycin overcomes ABC transporter-mediated
multidrug and apoptosis resistance in human leukemia stem cell-like
KG-1a cells. Biochem Biophys Res Commun. 394:1098–1104. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fuchs D, Heinold A, Opelz G, Daniel V and
Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis
resistance in human cancer cells. Biochem Biophys Res Commun.
390:743–749. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ketola K, Hilvo M, Hyötyläinen T, Vuoristo
A, Ruskeepää AL, Orešič M, Kallioniemi O and Iljin K: Salinomycin
inhibits prostate cancer growth and migration via induction of
oxidative stress. Br J Cancer. 106:99–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liang CC, Park AY and Guan JL: In
vitro scratch assay: A convenient and inexpensive method for
analysis of cell migration in vitro. Nat Protoc. 2:329–333.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Craene Band Berx G: Regulatory networks
defining EMT during cancer initiation and progression. Nat Rev
Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuwahara F, Kai H, Tokuda K, Kai M,
Takeshita A, Egashira K and Imaizumi T: Transforming growth
factor-beta function blocking prevents myocardial fibrosis and
diastolic dysfunction in pressure-overloaded rats. Circulation.
106:130–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Willis BC and Borok Z: TGF-beta-induced
EMT: Mechanisms and implications for fibrotic lung disease. Am J
Physiol Lung Cell Mol Physiol. 293:L525–L534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heldin CH, Vanlandewijck M and Moustakas
A: Regulation of EMT by TGFβ in cancer. FEBS Lett. 586:1959–1970.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufi S, Del Barco S, Martin-Castillo B and Menendez JA: Metformin
regulates breast cancer stem cell ontogeny by transcriptional
regulation of the epithelial-mesenchymal transition (EMT) status.
Cell Cycle. 9:3807–3814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao Z, Cheng X, Wang Y, Han R, Li L,
Xiang T, He L, Long H, Zhu B and He Y: Metformin inhibits the
IL-6-induced epithelial-mesenchymal transition and lung
adenocarcinoma growth and metastasis. PloS One. 9:e958842014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kuo SZ, Blair KJ, Rahimy E, Kiang A,
Abhold E, Fan JB, Wang-Rodriguez J, Altuna X and Ongkeko WM:
Salinomycin induces cell death and differentiation in head and neck
squamous cell carcinoma stem cells despite activation of
epithelial-mesenchymal transition and Akt. BMC Cancer. 12:5562012.
View Article : Google Scholar : PubMed/NCBI
|
